Regeneron's Eylea overtakes Lucentis with 2014 US sales
This article was originally published in Scrip
Executive Summary
Regeneron Pharmaceuticals reported $1.74bn in US sales for Eylea (aflibercept) in 2014, surpassing Roche's $1.7bn US total for the competing biologic Lucentis (ranibizumab), and a slightly higher Eylea growth rate is expected in 2015 based on increased use and new indications.
You may also be interested in...
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.